Allergan, Inc.

Compañía farmacéutica14 productos registrados

productos registrados

339.204

notificaciones totales

retiradas registradas

44,3%

graves en total

Productos

mostrando 14 de 14

Producto	Aprobado	Notificaciones ↓	Señal principal	Retiradas
prednisolone —	1955	188.016	Infección por citomegalovirus	33
onabotulinumtoxina —	1991	75.403	Uso múltiple de producto de un solo uso	0
linaclotide —	2012	25.697	flatulencia	1
prednisolone acetate —	1955	10.056	Endoftalmitis	8
cariprazine —	2015	8903	acatisia	1
brimonidine tartrate, timolol maleate —	—	6551	aumento de la presión intraocular	5
milnacipran hydrochloride —	2009	5952	Fibromialgia	0
ubrogepant —	2019	5632	Migraña	0
norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate —	—	3150	Amenorrea	0
eluxadoline —	2015	2902	Medicamento contraindicado prescrito	0
carboxymethylcellulose sodium and glycerin —	—	2372	Hiperemia escleral	0
levomilnacipran hydrochloride —	2013	1881	Síndrome de solapamiento	0
gatifloxacin —	2003	1747	Síndrome tóxico del segmento anterior	13
carboxymethylcellulose sodium, glycerin, and polysorbate 80 —	—	942	dolor en el párpado	0

Historial de retiradas · 39 registradas

Fecha	Clase	Motivo	Empresa
18 may 2026	III	Failed Stability Specifications	AbbVie Inc.
26 abr 2023	II	CGMP Deviations: Firm went out of business and could no longer continue stability studies.	Akorn, Inc.
7 oct 2022	II	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
1 ago 2022	II	Defective Container: Product has incomplete induction seals.	Akorn, Inc
13 abr 2022	II	cGMP deviations: Temperature abuse	Mckesson Medical-Surgical Inc. Corporate Office
22 dic 2021	III	Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.	Lupin Pharmaceuticals Inc.
20 oct 2021	III	Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.	Lupin Pharmaceuticals Inc.
15 mar 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mar 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
5 jun 2020	III	Discoloration: Out of Specification (OOS) result for APHA Color Test.	Akorn, Inc.
17 oct 2019	III	Labeling: Incorrect or missing package insert.	Sandoz Inc
23 sept 2019	II	Failed Impurities/Degradation Specifications - failed specs for Prednisolone Impurity 14	Morton Grove Pharmaceuticals, Inc.
6 sept 2019	III	Failed Impurities/Degradation Specifications:OOS for unknown impurity.	Mylan Pharmaceuticals Inc.
11 jul 2019	III	Labeling: Missing label; Product complaints reported missing bottle label.	Lupin Pharmaceuticals Inc.
17 dic 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17 dic 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17 dic 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17 dic 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17 dic 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
18 oct 2018	III	Presence of precipitate	Promise Pharmacy LLC
24 jul 2018	II	Defective Container: Tamper Evident foil seal not completely intact.	Morton Grove Pharmaceuticals, Inc.
30 abr 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
30 abr 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
30 abr 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
16 nov 2017	II	Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.	KRS Global Biotechnology, Inc
1 may 2017	II	Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.	Allergan Sales, LLC
28 mar 2017	III	Failed Stability Specifications	Teva Pharmaceuticals USA
20 sept 2016	II	Lack of Assurance of Sterility; all compounded products within expiry produced using recalled filters	Leiter's Compounding
12 sept 2015	II	Lack of Assurance of Sterility; The firm is recalling all sterile preparations that are within expiry due to deficient practices which may have an impact on sterility assurance.	US Compounding Inc
24 ago 2015	II	Presence of Particulate Matter: Due to customer complaints of small black particles, identified as part of the ointment tube cap, generated by the action of unscrewing the cap from the aluminum tube and potentially introducing the particle into the product.	Allergan Sales, LLC
14 nov 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14 nov 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14 nov 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14 nov 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
6 oct 2014	II	Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.	Oregon Compounding Centers, Inc. dba Creative Compounds
27 ago 2014	II	Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.	Martin Avenue Pharmacy, Inc.
19 oct 2013	II	Lack of Assurance of Sterility: All unexpired sterile compounded human and veterinary products are being recalled because they were compounded in the same environment and under the same practices as another product found to be non-sterile and therefore sterility cannot be assured.	Specialty Medicine Compounding Pharmacy
2 jul 2013	II	Labeling: Label Mixup; prednisoLONE, Tablet, 5 mg may be potentially mislabeled as ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg, NDC 00597000160, Pedigree: W003644, EXP: 8/24/2013.	Aidapak Services, LLC
21 may 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab

Clase I = probabilidad razonable de daño grave · Clase II = temporal o reversible · Clase III = improbable que cause daño.

Estado de registro

Algunos productos de Allergan, Inc. no están registrados por la FDA para uso humano. Para las sustancias no registradas (péptidos, SARM sin registro humano) no existe ningún proveedor legítimo para uso humano. La ausencia de una vía de aprovisionamiento es la información de seguridad.